Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DCPH Hot Sheet
Join SI Premium – FREE
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q2 EPS of ($0.60), $0.06 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $30.58 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Redwire Corporation (RDW) Tops Q3 EPS by 3c, Misses on Revenue; Offers FY26 Revenue Guidance
- MetLife (MET) Tops Q3 EPS by 3c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
